Oral administration of diclofenac in the prevention of post-ERCP pancreatitis: A double-blind, multicenter study.

Oral administration of diclofenac in the prevention of post-ERCP pancreatitis: A double-blind, multicenter study. - DBT of diclofenac in the prevention of post-ERCP pancreatitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008109

Enrollment

430

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-ERCP pancreatitis

Interventions

Diclofenac group is orally administered with 50mg diclofenac before and after ERCP. placebo group is orally administered with capsule filled with lactose before and after ERCP.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) age>20. 2) body weight >50kg. 3) Patients without sphincter of oddi dysfunction.

Exclusion criteria

Exclusion criteria: 1) Patients with hypersensitivity to diclofenac. 2) Patients with performance status 4. 3) Patients who are treated with diclofenac or received diclofenac within a week. 4) Patients with a history of EST and EPBD. 5) Patients with Vater tumor 6) Patients with divism 7) Patients with chronic pancreatitis 8) Patients with biliary pancreatitis 9) Patients who are judged inappropriate by chief (responsive) medical examiner.

Design outcomes

Primary

Measure	Time frame
incidence rate of post-ERCP pancreatitis	—

Countries

Japan

Contacts

Public ContactYuko Iwaizumi

Sapporo Medical University The 4th department of internal medicine

yuko-iwa@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026